Overview

TissueGene, Inc. has developed a proprietary cell technology with applications in the treatment and regeneration of damaged tissues such as cartilage and bones. The company uses a form of cell mediated therapy to deliver a regenerative protein to an area of damaged tissue, which catalyzes rapid and permanent repair of the injured site without the need for surgery.

  Technology

The Company’s patented technology consists of a novel method for inserting a therapeutic growth-factor gene into cells, culturing and stabilizing the genetically modified cells, and then injecting the modified cells into damaged tissue via a hypodermic needle. The modified cells then secrete therapeutic growth-factor proteins directly into the injured site, acting much like living “protein factories”, and induce tissue regeneration and repair. The Company has conducted pre-clincal animal studies using its technology with excellent results. Damaged cartilage in knee joints in rabbits and dogs, for example, has been effectively repaired through the injection of the Company’s modified cells.

  Advantages

• TissueGene offers permanent repair of damaged tissue (cartilage, ligaments, etc.).
  Other alternatives, such as arthroscopic surgery/debridement offer only temporary fixes.
• TissueGene's technology is easy to use and less risky because surgery is not required.
• TissueGene's technology is far less costly than other available technologies.
• TissueGene's technology can be mass-produced, packaged and delivered,
  unlike other available alternatives.
• TissueGene's technology can be easily and rapidly applied to a variety of debilitating diseases that cause degeneration of tissues.
• TissueGene's technology is applicable to major (full-thickness) cartilage defects as opposed to only minor (partial-thickness) defects.
• TissueGene's technology produces fully integrated hyaline cartilage, instead of partially integrated  hyaline cartilage with fibro-cartilage formations.